Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapies for immune-mediated diseases. Its lead programs center on RASP (reactive aldehyde species) modulators, including reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation being studied for retinal and vitreoretinal disorders. The company also has earlier-stage RASP-modulating candidates such as ADX-248 and ADX-246 aimed at systemic and retinal immune-mediated diseases. Aldeyra has no approved products and is still dependent on clinical progress, regulatory outcomes, and future partnering to create commercial revenue.

2.58

2.58

— Aldeyra Therapeutics, Inc.
%
Late-stage ophthalmology candidates60% Clinical-stage eye-disease programs focused on dry eye disease, allergic conjunctivitis, and retinal indications.
RASP-modulating small molecules25% Compounds designed to modulate reactive aldehyde species and broader immune pathways.
Intravitreal oncology/retinal formulations15% Specialty ophthalmic formulations such as ADX-2191 for vitreoretinal lymphoma and related retinal disorders.

Aldeyra does not currently sell approved products, so its near-term 'customers' are primarily regulators, clinical...

  • Ophthalmology prescribersprimary

    Eye-care physicians who would prescribe reproxalap if approved for dry eye disease or allergic conjunctivitis.

  • Retina and vitreoretinal specialistsprimary

    Specialists who would use ADX-2191 in rare retinal or vitreoretinal indications if approved.

  • Pharmaceutical partnersprimary

    Potential collaborators that may fund, develop, or commercialize the company's product candidates.

  • Clinical trial ecosystemsecondary

    Investigative sites, CROs, and investigators that conduct studies needed for regulatory approval.

Aldeyra is headquartered in Lexington, Massachusetts and is incorporated in Delaware, with operations centered in the...

  • •Headquartered in Lexington, Massachusetts, United States
  • •Incorporated in Delaware and managed from the U.S.
  • •Clinical and regulatory activity may extend outside the United States
  • •No approved-product revenue by country is currently disclosed
  • •Future commercialization could involve U.S. and ex-U.S. partners
  • •Geographic exposure is mainly trial, regulatory, and partnering related

Aldeyra's strategy is to advance reproxalap and ADX-2191 through late-stage development and secure regulatory approval...

01
Secure approval path for reproxalapshort-term

The company's future value is heavily dependent on whether its lead dry-eye asset can clear regulatory hurdles and reach market.

02
Partner for commercializationshort-term

Aldeyra has no commercial organization and expects to rely on third parties to market approved products.

03
Broaden the immune-modulating pipelinemedium-term

Pipeline diversification can reduce single-asset dependence and create additional shots on goal.

Aldeyra's most important risk is that reproxalap may not receive approval, may face delays, or may fail commercially...

high

Dependence on reproxalap

The company states that its business is dependent in large part on successful commercialization of reproxalap.

Scope
Lead asset concentration
Materiality
high
high

Regulatory approval uncertainty

The FDA has already issued a Complete Response Letter for ADX-2191, showing that approval outcomes are uncertain and can require additional evidence.

Scope
Pipeline approval risk
Materiality
high
high

Need for additional financing

The company has no product revenue and will need capital to continue development and prepare for commercialization.

Scope
Liquidity and dilution risk
Materiality
high
medium

Third-party trial execution

Clinical trials are conducted with external sites and partners, creating schedule and quality control risk.

Scope
Operational execution
Materiality
medium
medium

Competitive pressure in ophthalmology and immunology

Competitors may develop more effective or safer therapies, reducing the addressable market for Aldeyra's candidates.

Scope
Market share and differentiation
Materiality
medium
Accrued and deferred research and development expenses
Affects reported operating loss and quarterly comparability
Future collaboration and license accounting
Could affect future revenue timing and deferred revenue balances
Equity and convertible financing instruments
Can affect non-cash charges, EPS dilution, and balance sheet presentation

IDEAYA Biosciences, Inc.

IDYA · Pharmaceutical Preparations

Eledon Pharmaceuticals, Inc.

ELDN · Pharmaceutical Preparations

Coya Therapeutics, Inc.

COYA · Pharmaceutical Preparations

Edesa Biotech, Inc.

EDSA · Pharmaceutical Preparations

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

ALX ONCOLOGY HOLDINGS INC

ALXO · Pharmaceutical Preparations

: 11/08/2026